Does IPILIMUMAB Cause Immune-mediated hepatic disorder? 318 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 318 reports of Immune-mediated hepatic disorder have been filed in association with IPILIMUMAB (YERVOY). This represents 0.9% of all adverse event reports for IPILIMUMAB.
318
Reports of Immune-mediated hepatic disorder with IPILIMUMAB
0.9%
of all IPILIMUMAB reports
28
Deaths
130
Hospitalizations
How Dangerous Is Immune-mediated hepatic disorder From IPILIMUMAB?
Of the 318 reports, 28 (8.8%) resulted in death, 130 (40.9%) required hospitalization, and 21 (6.6%) were considered life-threatening.
Is Immune-mediated hepatic disorder Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for IPILIMUMAB. However, 318 reports have been filed with the FAERS database.
What Other Side Effects Does IPILIMUMAB Cause?
Death (3,710)
Malignant neoplasm progression (3,296)
Diarrhoea (2,557)
Off label use (2,097)
Colitis (1,988)
Pyrexia (1,796)
Rash (1,556)
Fatigue (1,447)
Intentional product use issue (1,329)
Nausea (1,169)
What Other Drugs Cause Immune-mediated hepatic disorder?
PEMBROLIZUMAB (923)
NIVOLUMAB (486)
CARBOPLATIN (188)
PACLITAXEL (144)
DURVALUMAB (102)
LENVATINIB (100)
PEMETREXED (67)
AXITINIB (53)
CABOZANTINIB S-MALATE (45)
TREMELIMUMAB\TREMELIMUMAB-ACTL (45)
Which IPILIMUMAB Alternatives Have Lower Immune-mediated hepatic disorder Risk?
IPILIMUMAB vs IPRAGLIFLOZIN L-PROLINE
IPILIMUMAB vs IPRATROPIUM
IPILIMUMAB vs IPRATROPIUM\IPRATROPIUM ANHYDROUS
IPILIMUMAB vs IPTACOPAN
IPILIMUMAB vs IRBESARTAN